Is InMode Ltd. (INMD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 66.3% / 30% | 5.9% / 30% | 6.73% / 5% | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 66.3% / 33% | 5.9% / 33% | 6.73% / 5% | ✗ NOT HALAL |
| MSCI | 1.1% / 33% | 72.5% / 33% | 6.4% / 33% | 6.73% / 5% | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 66.3% / 33% | 5.9% / 33% | 6.73% / 5% | ✗ NOT HALAL |
| FTSE | 1.1% / 33% | 72.5% / 33% | 6.4% / 50% | 6.73% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 78.5% | |
| Operating Margin | 25.0% | |
| Net Margin | 25.3% | |
| Return on Equity (ROE) | 13.5% | |
| Return on Assets (ROA) | 6.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $85M |
| Free Cash Flow | $84M |
| Total Debt | $8M |
| Debt-to-Equity | 1.2 |
| Current Ratio | 9.9 |
| Total Assets | $766M |
Price & Trading
| Last Close | $13.75 |
| 50-Day MA | $14.21 |
| 200-Day MA | $14.50 |
| Avg Volume | 1.1M |
| Beta | 2.2 |
|
52-Week Range
$12.72
| |
About InMode Ltd. (INMD)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is InMode Ltd. (INMD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), InMode Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is InMode Ltd.'s debt ratio?
InMode Ltd.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are InMode Ltd.'s key financial metrics?
InMode Ltd. has a market capitalization of $849M, trailing P/E ratio of 9.4, and revenue of $370M. The company maintains a gross margin of 78.5% and a net margin of 25.3%. Return on equity stands at 13.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.